Trexquant Investment LP Boosts Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Trexquant Investment LP lifted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 159.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 161,954 shares of the medical device company’s stock after acquiring an additional 99,631 shares during the quarter. Trexquant Investment LP owned 0.25% of Tandem Diabetes Care worth $4,791,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of TNDM. Eminence Capital LP increased its position in shares of Tandem Diabetes Care by 76.1% during the third quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company’s stock worth $114,028,000 after acquiring an additional 2,372,458 shares during the period. Jennison Associates LLC grew its stake in shares of Tandem Diabetes Care by 14.9% during the fourth quarter. Jennison Associates LLC now owns 1,290,590 shares of the medical device company’s stock worth $38,176,000 after purchasing an additional 167,675 shares in the last quarter. Banque Pictet & Cie SA acquired a new position in shares of Tandem Diabetes Care during the third quarter worth $2,295,000. Fred Alger Management LLC grew its stake in shares of Tandem Diabetes Care by 51.0% during the third quarter. Fred Alger Management LLC now owns 325,689 shares of the medical device company’s stock worth $6,765,000 after purchasing an additional 110,049 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Tandem Diabetes Care by 79.5% during the fourth quarter. Russell Investments Group Ltd. now owns 247,325 shares of the medical device company’s stock worth $7,316,000 after purchasing an additional 109,505 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages recently commented on TNDM. Lake Street Capital boosted their target price on shares of Tandem Diabetes Care from $60.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday. Stifel Nicolaus boosted their target price on shares of Tandem Diabetes Care from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday. Leerink Partnrs upgraded shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research note on Thursday, April 25th. StockNews.com upgraded shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Friday, April 19th. Finally, Barclays upped their price objective on shares of Tandem Diabetes Care from $39.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, May 6th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $49.73.

Tandem Diabetes Care Trading Up 4.2 %

Shares of TNDM opened at $51.39 on Thursday. Tandem Diabetes Care, Inc. has a fifty-two week low of $13.82 and a fifty-two week high of $52.51. The firm has a 50-day simple moving average of $36.78 and a 200-day simple moving average of $28.66. The company has a current ratio of 3.81, a quick ratio of 3.01 and a debt-to-equity ratio of 1.43.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Thursday, May 2nd. The medical device company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.17. The business had revenue of $191.67 million during the quarter, compared to the consensus estimate of $173.06 million. Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. Equities analysts forecast that Tandem Diabetes Care, Inc. will post -1.7 EPS for the current year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.